Following ACR Convergence 2020 we speak with Peter C Taylor (University of Oxford, Oxford, UK) about his highlights from the meeting.
Part 1 in the series covers the SEAM-RA study designed to investigate the effect of therapy reduction in RA patients with persistent submission receiving a combination of methotrexate and etanercept.
The abstract entitled ‘Maintenance of Remission After Withdrawal of Etanercept or Methotrexate in Patients with Rheumatoid Arthritis in Sustained Remission on Combination Therapy: Results from a Randomized, Double-blind, Controlled Trial’ was presented at ACR Convergence 2020.
Disclosures: Peter C Taylor reports receiving: Research grants from Celgene, Galapagos, Gilead and Lilly; and consultation fees from AbbVie, BMS, Biogen, Fresenius, Galapagos, Gilead, GlaxoSmithKline, Janssen, Lilly, Nordic Pharma, Pfizer, Roche, Sanofi, and UCB.
Support: Interview and filming supported by Touch Medical Media Ltd.
Filmed in coverage of virtual ACR Convergence 2020.
Share this Video
Related Videos In Rheumatoid Arthritis
Roy Fleischmann, ACR 2021: Efficacy and Safety of Olokizumab plus Methotrexate in a Placebo and Active Controlled Study
Dr Roy Fleischmann (University of Texas Southwestern Medical Center, Dallas, TX, USA) discusses the results from the phase 3, head-to-head, randomized, placebo-controlled clinical trial investigating olokizumab in patients with active rheumatoid arthritis inadequately controlled with methotrexate, with a comparator arm of adalimumab. The abstract entitled ‘Efficacy and Safety of Olokizumab in a Phase III Trial […]
Roy Fleischmann, ACR 2021: Safety and Efficacy of Tofacitinib vs TNF Inhibitors in ORAL Surveillance
It was a pleasure to speak with Dr Roy Fleischmann (University of Texas Southwestern Medical Center, Dallas, TX, USA) about ORAL Surveillance (NCT02092467). Mandated by the FDA, due to observed increases in lipids and malignancies in patients with RA treated with tofacitinib, this study was designed to investigate the relative risk of tofacitinib compared to […]
Gilles Boire, ACR 2021: A Mindfulness-Based Program to Improve PROs in patients with Rheumatoid Arthritis
It was a pleasure to discuss with Prof. Gilles Boire (Université de Sherbrooke, Québec, Canada) the recent pilot study in which a Mindfulness-Based Stress Reduction (MBSR) program was offered to patients with controlled rheumatoid arthritis but elevated negative PROs. The abstract entitled ‘Mindfulness-Based Stress Reduction (MBSR) to Improve Patient-Related Outcomes (PROs) in Patients with Rheumatoid […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!